Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry. The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to […]
Insulet
Insulet fully launches Omnipod 5 in Germany, expects full European availability by end of 2024
Insulet (Nasdaq:PODD) announced today that it commercially launched its Omnipod 5 automated insulin delivery system in Germany. Acton, Massachusetts-based Insulet released the device for individuals aged two years and older with type 1 diabetes. Germany marks the third market for the latest-generation patch pump. The company launched Omnipod 5 in the U.S. in August 2022, […]
Insulet raises 2023 guidance with Omnipod sales up 33%
Insulet (Nasdaq:PODD) stock is down today, even with Street-beating Q2 results and raised guidance. Shares of PODD were down more than 3% at $229.85 apiece by midday trading today. (Insulet announced its earnings yesterday evening.) MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down slightly. The […]
Report: Insulet prevails over Medtrum in France patent spat
According to a report in Europe, a Paris court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent. JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet. In declaring […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Insulet makes progress on integrating Omnipod 5 with Abbott FreeStyle Libre 2
Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development. Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego. Presentations include real-world evidence […]
Insulet makes Omnipod 5 automated insulin delivery system available in the UK
Insulet (Nasdaq:PODD) announced that it commercially launched its Omnipod 5 automated insulin delivery system in the United Kingdom. Acton, Massachusetts-based Insulet launched Omnipod 5 for individuals aged two years and older with type 1 diabetes. The latest-generation Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January […]
Analysts still high on Insulet despite Medtronic’s EOFlow buy, stock market reaction
Despite a negative reaction from investors following a major buy in the insulin delivery space, analysts still back Insulet (Nasdaq:PODD) stock to perform. Shares of PODD fell throughout today after Medtronic (NYSE:MDT) announced a $738 million acquisition of EOFlow. Korea-based EOFlow develops the EOPatch, a tubless, wearable and fully disposable insulin delivery device. Insulet represents […]
Insulet restructures leadership team to drive growth
Insulet (Nasdaq:PODD) announced today that it reshuffled its organizational structure to accelerate innovation and commercialization. In connection with the reorganization, Bret Christensen, EVP and chief commercial officer, leaves the company today to pursue other opportunities. He agreed to offer consulting services during a transition period. Jim Hollingshead, Insulet’s president and CEO, said Christensen “played an […]
